Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
FuelCell Energy Inc. Stock Sheds 4.0%, Underperforms Market

FuelCell Energy Inc. Stock Sheds 4.0%, Underperforms Market

Dow JonesDow Jones2026/08/24 20:34

This article was automatically generated by Dow Jones using technology from Automated Insights.

Shares of FuelCell Energy Inc. shed 4.0% to $18.75 on what proved to be an all-around mixed trading session for the stock market, with the Dow Jones Industrial Average rising 0.3% to 53,417.16 and the NASDAQ Composite Index falling 0.8% to 25,980.19.

FuelCell Energy Inc. closed 50.5% short of its 52-week high of $37.88, which the company achieved on June 30th.

Trading volume totaled 7.4 million, compared to the 50-day average of 11.6 million.

Data source: Dow Jones Market Data, FactSet

(END) Dow Jones Newswires

August 24, 2026 16:34 ET (20:34 GMT)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent

Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.

智通财经2026/09/22 07:56

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions

ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.

智通财经2026/09/22 07:21

Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.

The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.

智通财经2026/09/22 07:11